Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
McKesson
Harvard Business School
Merck
Moodys

Last Updated: June 28, 2022

Details for New Drug Application (NDA): 021016


✉ Email this page to a colleague

« Back to Dashboard

NDA 021016 describes RELPAX, which is a drug marketed by Upjohn and is included in one NDA. It is available from two suppliers. Additional details are available on the RELPAX profile page.

The generic ingredient in RELPAX is eletriptan hydrobromide. There are twelve drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the eletriptan hydrobromide profile page.
Summary for 021016
Tradename:RELPAX
Applicant:Upjohn
Ingredient:eletriptan hydrobromide
Patents:0
Pharmacology for NDA: 021016
Suppliers and Packaging for NDA: 021016
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
RELPAX eletriptan hydrobromide TABLET;ORAL 021016 NDA Roerig 0049-2330 0049-2330-45 6 BLISTER PACK in 1 CARTON (0049-2330-45) > 1 TABLET, FILM COATED in 1 BLISTER PACK (0049-2330-79)
RELPAX eletriptan hydrobromide TABLET;ORAL 021016 NDA Roerig 0049-2340 0049-2340-05 12 BLISTER PACK in 1 CARTON (0049-2340-05) > 1 TABLET, FILM COATED in 1 BLISTER PACK (0049-2340-79)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 20MG BASE
Approval Date:Dec 26, 2002TE:ABRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrengthEQ 40MG BASE
Approval Date:Dec 26, 2002TE:ABRLD:Yes

Expired US Patents for NDA 021016

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Upjohn RELPAX eletriptan hydrobromide TABLET;ORAL 021016-002 Dec 26, 2002 See Plans and Pricing See Plans and Pricing
Upjohn RELPAX eletriptan hydrobromide TABLET;ORAL 021016-001 Dec 26, 2002 See Plans and Pricing See Plans and Pricing
Upjohn RELPAX eletriptan hydrobromide TABLET;ORAL 021016-002 Dec 26, 2002 See Plans and Pricing See Plans and Pricing
Upjohn RELPAX eletriptan hydrobromide TABLET;ORAL 021016-001 Dec 26, 2002 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
Express Scripts
Johnson and Johnson
Mallinckrodt
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.